• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Acetanilides
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides Acetanilides

Recent Advances in the Study of 3',4'-Difluoroacetanilide (CAS: 458-11-7)

3',4'-Difluoroacetanilide (CAS: 458-11-7) is a fluorinated aromatic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and synthesis. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, particularly those targeting enzyme inhibition and receptor modulation. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, synthetic utility, and biological relevance.

Recent literature has emphasized the importance of 3',4'-Difluoroacetanilide in the development of novel kinase inhibitors. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its use as a precursor in the synthesis of selective EGFR (Epidermal Growth Factor Receptor) inhibitors, which are critical for targeting cancer cell proliferation. The fluorinated aromatic ring system of 3',4'-Difluoroacetanilide enhances the binding affinity of these inhibitors to the ATP-binding site of EGFR, thereby improving their therapeutic efficacy.

In addition to its role in kinase inhibition, 3',4'-Difluoroacetanilide has been investigated for its potential in antimicrobial applications. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported its incorporation into novel sulfonamide derivatives, which exhibited potent activity against drug-resistant bacterial strains. The presence of fluorine atoms in the compound was found to enhance the metabolic stability and bioavailability of these derivatives, making them promising candidates for further preclinical evaluation.

From a synthetic chemistry perspective, recent advancements have focused on optimizing the production of 3',4'-Difluoroacetanilide to improve yield and purity. A 2023 paper in Organic Process Research & Development detailed a streamlined, cost-effective synthesis route using palladium-catalyzed cross-coupling reactions. This method not only reduces the environmental impact of the synthesis but also scales efficiently for industrial production, addressing one of the key challenges in the commercialization of fluorinated pharmaceuticals.

The pharmacological profile of 3',4'-Difluoroacetanilide has also been a subject of recent investigation. In vitro and in vivo studies have shown that the compound exhibits favorable pharmacokinetic properties, including moderate plasma protein binding and good tissue penetration. These characteristics, combined with its low toxicity profile, make it an attractive scaffold for further medicinal chemistry optimization. Researchers are currently exploring its potential in central nervous system (CNS) drug development, given its ability to cross the blood-brain barrier.

In conclusion, 3',4'-Difluoroacetanilide (CAS: 458-11-7) represents a versatile and valuable building block in modern pharmaceutical research. Its applications span from oncology to infectious diseases, and ongoing studies continue to uncover new therapeutic possibilities. The compound's unique chemical properties, coupled with recent synthetic and pharmacological advancements, position it as a key player in the development of next-generation therapeutics. Future research should focus on expanding its utility in targeted drug delivery systems and combination therapies to maximize its clinical potential.

• 351-28-0(3'-Fluoroacetanilide)
• 57165-12-5(N-(4-amino-2-fluorophenyl)acetamide Hydrochloride hydrate)
• 351-83-7(4'-Fluoroacetanilide)
• 404-01-3(3',5'-Difluoroacetanilide)
• 3743-91-7(N-(4-acetamido-2,6-difluoro-phenyl)acetamide)
• 76778-13-7(2-Chloro-N-(3,4-difluorophenyl)acetamide)
• 653-22-5(Acetamide,N-(2,3,4,5,6-pentafluorophenyl)-)
• 3743-90-6(Acetamide,N-(4-amino-3,5-difluorophenyl)-)
• 3743-95-1(Acetamide,N-(4-amino-2,6-difluorophenyl)-)
• 1766-14-9(N-(2,3,5,6-Tetrafluorophenyl)acetamide)